Sandoz receives U.S. FDA approval to expand Enzeevu label

Sandoz (SDZNY) announced that the US Food and Drug Administration, FDA, has approved an expanded label for Enzeevu, to include multiple retinal indications. Enzeevu was originally approved by the FDA for the treatment of neovascular age-related macular degeneration, nAMD, in August 2024. Keren Haruvi, President Sandoz North America said: “More than 30 million people in the US are living with retinal diseases that can lead to irreversible vision loss or blindness. With this expanded label, we’re broadening our ability to deliver affordable care to those impacted by these devastating diseases.”